60 Degrees Pharmaceuticals’ (SXTP) “Neutral” Rating Reiterated at HC Wainwright

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “neutral” rating reiterated by equities researchers at HC Wainwright in a research note issued to investors on Friday,Benzinga reports.

60 Degrees Pharmaceuticals Stock Performance

NASDAQ:SXTP opened at $0.90 on Friday. The firm’s 50-day moving average is $1.09 and its 200-day moving average is $0.72. 60 Degrees Pharmaceuticals has a 52-week low of $0.70 and a 52-week high of $18.36.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($4.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.79) by ($1.44). The company had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $0.11 million. Sell-side analysts forecast that 60 Degrees Pharmaceuticals will post -3.17 earnings per share for the current year.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.